Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Restoring Insulin Secretion Pediatric Medication Study

Next Previous
X
Search
Trial Profile

Restoring Insulin Secretion Pediatric Medication Study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin glargine (Primary) ; Metformin (Primary)
  • Indications Prediabetic state; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms RISE Peds

    • Most Recent Events

    • 16 Jun 2021 Results from the three RISE study (NCT01779362, NCT01779375 and NCT01763346) assessing the effect of Liraglutide and metformin in adults would improve a-cell function beyond any potential effect of weight loss, published in the Diabetes Care.
    • 15 Jun 2021 Results assessing the comparing the glycemic worsening between youth and adult RISE participants with IGT or recently diagnosed type 2 diabetes and identify baseline characteristics that predict glycemic worsening in each group, published in the Diabetes Care.
    • 12 Jan 2021 Results examining the glucose response curves during an oral glucose tolerance test (OGTT) and their relationship to insulin sensitivity (IS) and B cell function in youth versus adults with impaired glucose tolerance or recently diagnosed type 2 diabetes published in the Diabetes Care
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top